Croda International - Britains Most Admired Company for Innovation
Yorkshire-based Croda International, manufacturers of speciality chemical ingredients that enhance everyday consumer and industrial products, has just been awarded first place in the innovation segment, second in the chemical sector category and eighth place overall in the 2014 Britain’s Most Admired Companies Awards.
The Management Today awards are the largest awards of their kind in the UK; they highlight corporate reputation by recognising key factors critical to business success, with winners identified by means of peer review.
Steve Foots, Chief Executive of Croda said: “To be named Britain’s most Innovative Company is a fantastic accolade and we are hugely proud to collect this award. Innovation runs through every part of our business and for this to be recognised by industry peers, and the investment community, is testament to the dedication and hard work of our employees across the globe.”
Organisations are scored against nine performance areas; from quality of management, financial soundness and quality of goods and services, to the ability to attract, develop and retain top talent, the capacity to innovate and commitment to community and environmental responsibility. Opinions on these areas are sought from more than 200 Board members at some of the UK’s largest companies, as well as analysts and City commentators.
Commenting on the results, Matthew Gywther, editor of Management Today said; “Croda took the 2014 criteria award for Capacity to Innovate, in recognition of its world-class reputation for generating new ideas for its customers and bringing them to market.
“Researched by Prof Mike Brown and his team at Birmingham City University, and with a history dating back over 20 years, Britain's Most Admired Companies provides a fascinating insight into that most hard-won of intangible assets, corporate reputation.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.